Article

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistance

2026-05-25

Abstract excerpt

Although platinum salts or PARP inhibitors are effective in delivering anti-tumor responses in people with BRCA1 or BRCA2 mutated cancers, drug resistance is common and is often caused by secondary BRCA1/2 reversion mutations that restore function. By collating and analyzing 848 BRCA1/2 reversion mutations in 384 cancer patients with drug resistance, we confirm that pathogenic BRCA1/2 mutation type influences...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7b6ddc0d-c514-5992-b25d-455673b91d26
DOI: 10.64898/2026.05.22.727163

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistanceDOI 10.64898/2026.05.22.727163Read

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.Semantic proximity Read

A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity Read

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.Semantic proximity Read

BRCA1/2 reversion mutations in a pan-cancer cohort.Semantic proximity Read

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Semantic proximity Read

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.Semantic proximity Read

Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer PatientsSemantic proximity Read

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.Semantic proximity Read

Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.Semantic proximity Read